Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Salud pública Méx ; 60(3): 338-346, may.-jun. 2018. tab, graf
Artigo em Espanhol | LILACS | ID: biblio-979146

RESUMO

Resumen: Objetivo: Evaluar la cobertura de vacunación en menores de siete años. Material y métodos: Estudio basado en la Encuesta Nacional de Salud y Nutrición de Medio Camino 2016. Resultados: La cobertura de esquema completo en los niños menores de un año fue de 51.7% [rango: de 67.6%, para la vacuna pentavalente (PV), a 93.9%, para la vacuna Bacillus Calmette-Guerin (BCG)]; en los de 12-23 meses fue de 53.9% [rango: de 68.5%, para la vacuna triple viral (SRP), a 98.3%, para la BCG], y en los de 24-35 meses, de 63.2% [rango: de 85.3%, para la vacuna contra neumococo, a 98.6%, para la BCG]. En niños de seis años, la cobertura de una dosis de SRP fue de 97.8%, y para dos dosis, de 50.7%. Sólo 2.2% de los niños de seis años no estaban vacunados. Las variables asociadas con esquema incompleto fueron edad de 2-5 meses, madre menor de 20 años o hablante de lengua indígena. Conclusiones: Debe mejorarse el reclutamiento de recién nacidos al programa de vacunación, así como su seguimiento, hasta completar el esquema, aprovechando los contactos con los servicios de salud para vacunarlos.


Abstract: Objective: To assess vaccination coverage in children under seven years of age. Materials and methods: Study based on the Halfway National Health and Nutrition Survey (Ensanut MC 2016). Results: Full vaccination coverage in children <1 year was 51.7%, (range: 67.6% [pentavalent (PV)] to 93.9% [BCG]), in those aged 12-23 months was 53.9% (range: 68.5% [MMR] to 98.3% [BCG]) and in those 24-35 months was 63.2% (range: 85.3% [pneumococcal]) to 98.6% [BCG]). In children aged six years, the coverage of 1 MMR dose was 97.8% and 50.7% for two doses. Only 2.2% of six year olds were not vaccinated. Variables associated with incomplete schedule were age of 2-5 months, mother being under 20 years of age or maternal language indigenous. Conclusions: The vaccination program needs to improve recruitment of newborns and their follow-up until they complete their immunization schedule, taking advantage of the local contacts with health services to vaccinate them.


Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Criança , Esquemas de Imunização , Cobertura Vacinal/estatística & dados numéricos , México
2.
Salud Publica Mex ; 60(3): 338-346, 2018.
Artigo em Espanhol | MEDLINE | ID: mdl-29746751

RESUMO

OBJECTIVE: To assess vaccination coverage in children under seven years of age. MATERIALS AND METHODS: Study based on the Halfway National Health and Nutrition Survey (Ensanut MC 2016). RESULTS: Full vaccination coverage in children <1 year was 51.7%, (range: 67.6% [pentavalent (PV)] to 93.9% [BCG]), in those aged 12-23 months was 53.9% (range: 68.5% [MMR] to 98.3% [BCG]) and in those 24-35 months was 63.2% (range: 85.3% [pneumococcal]) to 98.6% [BCG]). In children aged six years, the coverage of 1 MMR dose was 97.8% and 50.7% for two doses. Only 2.2% of six year olds were not vaccinated. Variables associated with incomplete schedule were age of 2-5 months, mother being under 20 years of age or maternal language indigenous. CONCLUSIONS: The vaccination program needs to improve recruitment of newborns and their follow-up until they complete their immunization schedule, taking advantage of the local contacts with health services to vaccinate them.


OBJETIVO: Evaluar la cobertura de vacunación en menores de siete años. MATERIAL Y MÉTODOS: Estudio basado en la Encuesta Nacional de Salud y Nutrición de Medio Camino 2016. RESULTADOS: La cobertura de esquema completo en los niños menores de un año fue de 51.7% [rango: de 67.6%, para la vacuna pentavalente (PV), a 93.9%, para la vacuna Bacillus Calmette-Guerin (BCG)]; en los de 12-23 meses fue de 53.9% [rango: de 68.5%, para la vacuna triple viral (SRP), a 98.3%, para la BCG], y en los de 24-35 meses, de 63.2% [rango: de 85.3%, para la vacuna contra neumococo, a 98.6%, para la BCG]. En niños de seis años, la cobertura de una dosis de SRP fue de 97.8%, y para dos dosis, de 50.7%. Sólo 2.2% de los niños de seis años no estaban vacunados. Las variables asociadas con esquema incompleto fueron edad de 2-5 meses, madre menor de 20 años o hablante de lengua indígena. CONCLUSIONES: Debe mejorarse el reclutamiento de recién nacidos al programa de vacunación, así como su seguimiento, hasta completar el esquema, aprovechando los contactos con los servicios de salud para vacunarlos.


Assuntos
Esquemas de Imunização , Cobertura Vacinal/estatística & dados numéricos , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , México
3.
Int J Epidemiol ; 35(6): 1447-54, 2006 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17008360

RESUMO

BACKGROUND: The tuberculin skin test (TST) is the most commonly used tool to detect infection with Mycobacterium tuberculosis. We sought to determine whether tuberculin skin testing is useful to detect latent infection by M. tuberculosis in a population that was vaccinated with the Bacille Calmette Guérin (BCG) vaccine. METHODS: We performed a cross-sectional study during October 2000-February 2001, enrolling first and sixth graders from a random, stratified sample of public elementary schools in Orizaba, Veracruz, Mexico. We assessed the relationship between sociodemographic and epidemiological information, BCG scars, and TST reactivity. RESULTS: There were 858 children enrolled in the study with a completed questionnaire and TST result. The prevalence of a positive TST result (> or =10 mm) was 12.4%. Controlling for BCG scar, age, and other characteristics, close contact with pulmonary tuberculosis patients (odds ratio 6.56, 95% confidence interval 2.05-21.07, P = 0.001) was independently associated with TST reactivity. CONCLUSIONS: TST results helped identify children in a BCG-vaccinated population who had recent exposure to persons with pulmonary tuberculosis, were probably infected with M. tuberculosis, and could benefit from treatment for their latent tuberculosis infection.


Assuntos
Vacinas Bacterianas/uso terapêutico , Mycobacterium bovis/imunologia , Teste Tuberculínico/métodos , Tuberculose Pulmonar/diagnóstico , Adolescente , Distribuição por Idade , Criança , Pré-Escolar , Estudos Transversais , Exposição Ambiental/efeitos adversos , Feminino , Humanos , Masculino , México/epidemiologia , Mycobacterium tuberculosis/imunologia , Prevalência , Fatores de Risco , Distribuição por Sexo , Tuberculose Pulmonar/epidemiologia , Tuberculose Pulmonar/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA